Solid tumors and hamatological malignancies
Conditions
Brief summary
Safety as assessed by incidence of all AEs of special interest, Grade 3, 4, or 5 AEs, Grade 2 AEs that affect vital organs (eg, heart, liver, brain, lung, kidney), nonserious AEs that lead to dose modification or drug discontinuation or withdrawal from the trial, and SAEs of any severity.
Detailed description
Overall survival defined as the time from start of treatment in parent study (or randomization date for a randomized study) until the date of death from any cause.
Interventions
Sponsors
BeOne Medicines AG
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Safety as assessed by incidence of all AEs of special interest, Grade 3, 4, or 5 AEs, Grade 2 AEs that affect vital organs (eg, heart, liver, brain, lung, kidney), nonserious AEs that lead to dose modification or drug discontinuation or withdrawal from the trial, and SAEs of any severity. | — |
Secondary
| Measure | Time frame |
|---|---|
| Overall survival defined as the time from start of treatment in parent study (or randomization date for a randomized study) until the date of death from any cause. | — |
Countries
France, Italy, Poland
Outcome results
None listed